LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, has announced it will release its third quarter 2024 financial results before market open on Thursday, November 7, 2024. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss financial results and recent corporate highlights. Participants can join via telephone or access the live webcast through LENSAR's website investor section.
LENSAR (Nasdaq: LNSR), un'azienda globale nel settore della tecnologia medica specializzata in soluzioni laser robotiche per il trattamento della cataratta, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura dei mercati giovedì 7 novembre 2024. L'azienda organizzerà una teleconferenza e una webseminar alle 8:30 ora ET lo stesso giorno per discutere i risultati finanziari e i recenti punti salienti aziendali. I partecipanti possono unirsi per telefono o accedere al webcast live attraverso la sezione investitori del sito web di LENSAR.
LENSAR (Nasdaq: LNSR), una empresa global de tecnología médica especializada en soluciones láser robóticas para el tratamiento de cataratas, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el jueves 7 de noviembre de 2024. La compañía organizará una conferencia telefónica y un webcast a las 8:30 a.m. ET el mismo día para discutir los resultados financieros y los recientes destacados corporativos. Los participantes pueden unirse por teléfono o acceder al webcast en vivo a través de la sección de inversores del sitio web de LENSAR.
LENSAR (Nasdaq: LNSR)는 백내장 치료를 위한 로봇 레이저 솔루션을 전문으로 하는 글로벌 의료 기술 회사로, 2024년 3분기 재무 결과를 2024년 11월 7일 목요일 장이 열리기 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 재무 결과 및 최근 기업 하이라이트에 대해 논의하기 위한 전화 회의 및 웹캐스트를 개최할 예정입니다. 참가자는 전화로 참여하거나 LENSAR 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다.
LENSAR (Nasdaq: LNSR), une entreprise mondiale de technologie médicale spécialisée dans les solutions laser robotiques pour le traitement de la cataracte, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés le jeudi 7 novembre 2024. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30 ET le même jour pour discuter des résultats financiers et des faits marquants récents de l'entreprise. Les participants peuvent se joindre par téléphone ou accéder au webinaire en direct via la section investisseurs du site Web de LENSAR.
LENSAR (Nasdaq: LNSR), ein globales Medizintechnologieunternehmen, das auf robotergestützte Laserlösungen zur Behandlung von Katarakten spezialisiert ist, hat bekannt gegeben, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am Donnerstag, den 7. November 2024, veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und aktuelle Unternehmenshighlights zu besprechen. Teilnehmer können sich telefonisch einwählen oder über den Investorenbereich der LENSAR-Website auf den Live-Webcast zugreifen.
- None.
- None.
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline ® software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | Lee Roth / Cameron Radinovic | |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR | |
| ir.contact@lensar.com | lroth@burnsmc.com / cradinovic@burnsmc.com |
FAQ
When will LENSAR (LNSR) release Q3 2024 earnings?
How can I join LENSAR's (LNSR) Q3 2024 earnings call?
What time is LENSAR's (LNSR) Q3 2024 earnings call?
